Actionable insights straight to your inbox


Five Fallen Biotech Stocks We’re Watching for Rebounds

We think opportunities abound in the sector.

Image source: Chokniti Khongchum / Pixabay

Biotech investors have generally been on the wrong end of the trade in 2022, with poor absolute performance and relative performance that lags the market.

The Nasdaq Biotechnology Index is off 19.2% year-to-date, compared to an 18.7% decline for the Nasdaq Composite and a 10.6% loss for the S&P 500 Index.

In an environment where the megacap technology stocks lead the market in both directions, we think investors who are willing to take the time to do a little research can find opportunities in biotech and life sciences, particularly at the smaller end of the market cap spectrum.

We highlight five today that we're watching for potential rebounds over the next 12 months:


Innate Pharma (IPHA - $2.85 0.11 (3.778%)  )


BioXcel Therapeutics (BTAI - $18.66 0.06 (0.323%)  )


Editas Medicine (EDIT - $7.25 0.22 (3.129%)  )


Affimed (AFMD - $0.75 0.0048 (0.648%)  )


Genfit (GNFT - $4.10 0. (0%)  )


Which companies are you following, biotech or otherwise? Let us know, and we promise to write about several of the submissions. Please email us at [email protected].

Thank you.


Source: Equities News




With pandemic-induced supply chain bottlenecks receding, semiconductor stocks have been riding a bullish trend, making higher lows and higher highs.
To say the current situation isn’t pretty now seems an understatement, and it’s likely to remain chaotic for a while. Which is why it’s so important for leaders of all kinds not to fall prey to the very human tendency to go negative.
Bargain-hunting friends of mine have been asking: “Should I buy First Republic?” After all, First Republic is prestigious. Facebook founder Mark Zuckerberg got a mortgage there. Dozens of customer surveys rate its satisfaction scores higher than super-brands like Apple and Ritz-Carlton.
Many of us economy-watchers have been expecting recession, though with significant differences on odds and timing. Regardless, recent banking developments just made recession more likely and may have accelerated its onset.